AU752676B2 - Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues - Google Patents

Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues Download PDF

Info

Publication number
AU752676B2
AU752676B2 AU94410/98A AU9441098A AU752676B2 AU 752676 B2 AU752676 B2 AU 752676B2 AU 94410/98 A AU94410/98 A AU 94410/98A AU 9441098 A AU9441098 A AU 9441098A AU 752676 B2 AU752676 B2 AU 752676B2
Authority
AU
Australia
Prior art keywords
cells
site
monocyte derived
agents
derived cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU94410/98A
Other languages
English (en)
Other versions
AU9441098A (en
Inventor
Jacques Bartholeyns
Mohamed Chokri
Patrick A. Dreyfus
Luis Garcia
Elaine Parrish
Elise Peltekian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IDM Immuno Designed Molecules
Institut National de la Santé et de la Recherche Médicale
Original Assignee
IDM Immuno Designed Molecules
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IDM Immuno Designed Molecules, Institut National de la Santé et de la Recherche Médicale filed Critical IDM Immuno Designed Molecules
Publication of AU9441098A publication Critical patent/AU9441098A/en
Application granted granted Critical
Publication of AU752676B2 publication Critical patent/AU752676B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
AU94410/98A 1997-09-05 1998-08-31 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues Ceased AU752676B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/924,830 US20020068048A1 (en) 1997-09-05 1997-09-05 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
US08/924830 1997-09-05
PCT/EP1998/005707 WO1999013054A2 (en) 1997-09-05 1998-08-31 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues

Publications (2)

Publication Number Publication Date
AU9441098A AU9441098A (en) 1999-03-29
AU752676B2 true AU752676B2 (en) 2002-09-26

Family

ID=25450795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU94410/98A Ceased AU752676B2 (en) 1997-09-05 1998-08-31 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues

Country Status (7)

Country Link
US (2) US20020068048A1 (cg-RX-API-DMAC10.html)
EP (1) EP1009806A2 (cg-RX-API-DMAC10.html)
JP (1) JP2001515713A (cg-RX-API-DMAC10.html)
AU (1) AU752676B2 (cg-RX-API-DMAC10.html)
CA (1) CA2300387A1 (cg-RX-API-DMAC10.html)
IL (1) IL134393A0 (cg-RX-API-DMAC10.html)
WO (1) WO1999013054A2 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060054A1 (en) * 1999-04-06 2000-10-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
AU1375301A (en) * 1999-11-15 2001-05-30 Bio Syntech Canada Inc Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution
AU5159901A (en) * 2000-04-14 2001-10-30 Univ Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
EP1335687B1 (en) * 2000-11-15 2007-01-10 Bio Syntech Canada Inc. Method for restoring a damaged or degenerated intervertebral disc
KR101114784B1 (ko) 2002-11-12 2012-02-27 예일 유니버시티 아데노바이러스 벡터 백신
ATE482713T1 (de) * 2003-04-25 2010-10-15 Univ Pittsburgh Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und - regeneration
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US9044381B2 (en) 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
RU2006144851A (ru) 2004-06-15 2008-06-20 Бакстер Интернэшнл Инк. (Us) Применение терапевтических средств ex-vivo в виде твердых микрочастиц
US20100178355A1 (en) * 2006-11-30 2010-07-15 Hoemann Caroline D Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications
RU2496482C2 (ru) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
EP2328596B1 (en) * 2008-08-18 2019-03-06 University of Pittsburgh - Of the Commonwealth System of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
GB201504251D0 (en) 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7539894A (en) * 1993-08-25 1995-03-21 Institut National De La Sante Et De La Recherche Medicale Recombinant cells from the monocyte-macrophage cell line for gene therapy
AU4626596A (en) * 1995-01-24 1996-08-14 I.D.M. Immuno-Designed Molecules Process for preparing macrophages, and kits and compositions therefore

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7539894A (en) * 1993-08-25 1995-03-21 Institut National De La Sante Et De La Recherche Medicale Recombinant cells from the monocyte-macrophage cell line for gene therapy
AU4626596A (en) * 1995-01-24 1996-08-14 I.D.M. Immuno-Designed Molecules Process for preparing macrophages, and kits and compositions therefore

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GENE THERAPY, 1996, 3(1), PARRISH ET AL., 13-20 *

Also Published As

Publication number Publication date
IL134393A0 (en) 2001-04-30
WO1999013054A3 (en) 1999-05-06
JP2001515713A (ja) 2001-09-25
US20050048039A1 (en) 2005-03-03
CA2300387A1 (en) 1999-03-18
AU9441098A (en) 1999-03-29
WO1999013054A2 (en) 1999-03-18
US20020068048A1 (en) 2002-06-06
EP1009806A2 (en) 2000-06-21

Similar Documents

Publication Publication Date Title
Gravel et al. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons
Tai et al. Gene transfer of glial cell line-derived neurotrophic factor promotes functional recovery following spinal cord contusion
Frautschy et al. Localization of basic fibroblast growth factor and its mRNA after CNS injury
Sagot et al. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse
AU772340B2 (en) Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
Kramer et al. Gene transfer through the blood–nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis
Lu et al. Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice
CN102886052B (zh) 长效药物制剂
Finiels et al. Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neurone diseases
Lu et al. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport
US20050048039A1 (en) Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
JPH11507201A (ja) 筋肉の疾患および障害の治療方法
US20240108652A1 (en) Enhancing metabolic fitness of t cells to treat cancer
US12343420B2 (en) Stabilized polyribonucleotide coding for an elastic fibrous protein
Cunningham et al. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease
US6451306B1 (en) Methods for therapy of neurodegenerative disease of the brain
Martinez‐Serrano et al. Ex vivo gene transfer of brain‐derived neurotrophic factor to the intact rat forebrain: neurotrophic effects on cholinergic neurons
Bankiewicz et al. Practical Aspects of the Development ofex Vivoandin VivoGene Therapy for Parkinson's Disease
Barami et al. Cellular transplantation and spinal cord injury
KR20010093804A (ko) 심근증 유전자 치료
US20020187936A1 (en) Methods of treating liver disease and liver damage with growth hormone and foxM1B
Kato et al. Nonviral HVJ (hemagglutinating virus of Japan) liposome-mediated retrograde gene transfer of human hepatocyte growth factor into rat nervous system promotes functional and histological recovery of the crushed nerve
Joung et al. Effective Gene Transfer into Regenerating Sciatic Nerves by Adenoviral Vectors: Potentials for Gene Therapy of Peripheral Nerve Injury: Insil Joung et al.
JP2001515713A5 (cg-RX-API-DMAC10.html)
Tuszynski et al. Somatic gene transfer to the adult primate central nervous system: in vitroandin vivocharacterization of cells genetically modified to secrete nerve growth factor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)